Findings

What do systematic reviews say?

5 questions · 6 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 0 · 0%Moderate 4 · 66.7%High 0 · 0%

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

2 findings from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 125 participants
Very low
Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Quality of life: change from baseline in CFQ‐R · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate

Change in BMI · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Moderate

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Adverse events · adults and children with cystic fibrosis

Summary of findings: oral antioxidants (NAC/GSH) showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
OR 2.92 [0.11, 74.05]
1 study · 70 participants
Moderate